>> Press release archive

Sign up to our newsletter
Stay up-to-date on all our news and activities

press releases


Eleven million euros for Dortmund alliance for the development of new lead compounds

Innovative network of eight partners for North Rhine-Westphalia

Drug Discovery Hub Dortmund (DDHD) is the name of the new initiative at the Zentrum für integrierte Wirkstoffforschung (ZIW) of the TU Dortmund University (TU), which got started on 1 April 2018. Scientists from eight institutions combine their manifold expertise to develop an infrastructure for drug discovery in North Rhine-Westphalia. In addition to the TU Dortmund, the Max-Planck-Institute for Molecular Physiology (MPI), the Leibniz Research Centre for Working Environment and Human Factors (IfADo), the Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., the Taros GmbH & Co. KG, the PROvendis GmbH, the BioMedizinZentrum Dortmund (BMZ), and the Lead Discovery Center GmbH (LDC) are participating.

>> Continue >> download PDF



LDC: New branch for development of therapeutic antibodies in Munich

The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emphasis will be on the development of therapeutic antibodies.

>> Continue >> download PDF



Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration

Daiichi Sankyo, Max Planck Innovation and LDC have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at LDC.

>> Continue >> download PDF



LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for Biology of Ageing and jointly advanced by the LDC and Max Planck scientists into drug discovery.


>> Continue >> download PDF



Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

First project from LDC's agreement with Arix

Arix Bioscience plc (LSE:ARIX), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center, Max Planck Innovation, and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.

>> Continue >> download PDF

>> click here



LDC and UGISense AG to Collaborate on New Drug Class

Lead Discovery Center GmbH (LDC) and the biotech company UGISense AG are about to initiate a collaboration to jointly develop innovative drugs using the proprietary UgimeresTM antisense platform.

>> Continue >> download PDF



LDC Teams up with Canadian McGill University in $1 Million Translational Drug Discovery Project


First research project to be funded under the Canada/Germany Program

Researchers from the Lead Discovery Center (LDC) in Dortmund, Germany led by Dr. Bert Klebl and McGill University in Montréal, Canada led by Dr. David Y. Thomas will work closely together to identify novel tools for protein trafficking and folding diseases drug discovery.The 3-years research initiative between LDCand McGill University will be funded for a total of $1M.

>> Continue >> download PDF



LDC and Boehringer Ingelheim Join Forces to Discover a Novel Approach for the Treatment of Schizophrenia

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC.

>> Continue >> download PDF



LDC Enters new Industry Partnership for the Discovery of Novel Medicines


LDC and Roche will jointly advance innovative drug discovery projects


The Lead Discovery Center GmbH (LDC) and Roche will collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need across several disease areas.

>> Continue >> download PDF



news & press

Response to the structural transformation of the pharma industry [German only]

Bert Klebl, Peter Nussbaumer and Matthias Stein-Gerlach; transkript | Special Issue Kapital & Börse May 2009

>> download PDF >> Transkript Online


Polishing Medical Rough Diamonds

Text: Marcus Anhäuser
Max Planck Society Magazine Special “Innovation” / 2009
Pages 47 – 53

>> download PDF >> Max Planck multimedial


Joint Initiative for Research and Innovation


>> Link